United Neuroscience Ltd. and the Boston University Lee Goldstein Laboratory have signed a collaboration agreement to research tau-targeted therapeutics for the treatment and prevention of Chronic Traumatic Encephalopathy (CTE).
United Neuroscience Ltd. and the Lee Goldstein laboratory at the Boston University School of Medicine have signed a collaboration agreement to investigate potential Endbody vaccines to target pathogenic forms of tau protein. “Targeting specific forms of tau with this technology could provide a significant opportunity to benefit those at risk of neurodegenerative disease,” said Lee Goldstein, M.D., Ph.D., Director of Molecular Agig and Development Laboratory, Neurotrauma Laboratory and Associate Professor at the Boston University School of Medicine, adding: “We are excited to work with United Neuroscience to explore the potential of tau protein-targeted therapeutics in CTE using their Endobody vaccine technology.” Mei Mei Hu, Chief Executive Officer of United Neuroscience stated: "The Lee Goldstein laboratory has made key contributions to the understanding of CTE pathology. Their support in defining a path toward development of an effective therapeutic helps ensure that we are incorporating the best knowledge currently available in the field."
Ajay Verma, M.D., Ph.D., Chief Medical Officer of United Neuroscience, went on to say that the development of an Endbody therapeutic would be an extremely promising approach to valuate for individuals at risk for chronic traumatic encephalopathy. Candidates will be evaluated using postmortem tissue samples, as well as preclinical models of disease biology for potential in prevention and treatment CTE.